Xing-yu Cao

Dr. Xing-yu Cao


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
XCXing-yu Cao
Xing-yu Cao
JZJian-Ping Zhang
Jian-Ping Zhang
YZYan-Li Zhao
Yan-Li Zhao
MXMin Xiong
Min Xiong
JZJia-Rui Zhou
Jia-Rui Zhou
PLPeihua Lu
Peihua Lu
Background: Chimeric antigen receptor (CAR) T-cell therapy has demonstrated high initial complete remission (CR) rates in B-cell acute lymphoblastic leukemia (B-ALL) patients, including those who relapsed after transplant. However, the duration of remission requires improvements. Whether bridging to a second allogeneic hematopoietic stem cell transplant (allo-HSCT) after CAR-T therapy can improve long-term survival remains controversial. We retrospectively analyzed long-term follow-up data of B-ALL patients who relapsed post-transplant and received CAR-T therapy followed by consolidation second allo-HSCT to investigate whether such a treatment sequence could improve long-term survival.Methods: A single-center, retrospective study was performed between October 2017 and March 2022, involving 95 patients who received a consolidation second transplant after achieving CR from CAR-T therapy.Results: The median age of patients was 22.8 years (range: 3.3-52.8) at the second transplant. After the first transplant, 71 patients (74.7%) experienced bone marrow relapse, 16 patients (16.8%) had extramedullary relapse, 5 patients (5.3%) had both bone marrow and extramedullary relapse and 3/95 patients (3.2%) had positive minimal residual disease (MRD) only. Patients received autologous (n=57, 60.0%) or allogeneic (n=28, 29.5%) CAR-T cells, while 10 patients (10.5%) were unknown. All patients achieved CR after CAR-T therapy. Before second HSCT, 86 patients (90.5%) were MRD-negative, and 9 (9.5%) were MRD-positive. All second transplant donors were different from the first transplant donors. The median follow-up time was 623 days (range: 33-1901) after the second HSCT. The 3-year overall survival (OS) and leukemia-free survival (LFS) were 55.3% (95%CI, 44.3-66.1%) and 49.8% (95%CI, 38.7-60.9%), respectively. The 3-year relapse incidence (RI) and non-relapse mortality (NRM) were 10.5% (95%CI, 5.6-19.6%) and 43.6% (95%CI, 33.9-56.2%), respectively. In multivariate analysis, the interval from CAR-T to second HSCT ≤90 days was associated with superior LFS(HR, 4.10, 95%CI,1.64-10.24; p=0.003) and OS(HR, 2.67, 95%CI, 1.24-5.74, p=0.012), as well as reduced NRM (HR, 2.45, 95%CI, 1.14-5.24, p=0.021).Conclusions: Our study indicated that CAR-T therapy followed by consolidation second transplant could significantly improve long-term survival in B-ALL patients who relapsed post-transplant. The second transplant should be considered in suitable patients and is recommended to be performed within 90 days after CAR-T treatment.

13 April 2024 in British Journal of Haematology
Verified
Journal Article
Closed access
XCXing-yu Cao
Xing-yu Cao
JZJian‐Ping Zhang
Jian‐Ping Zhang
YLYue Lu
Yue Lu
YZYan‐Li Zhao
Yan‐Li Zhao
DLDe‐Yan Liu
De‐Yan Liu
PLPeihua Lu
Peihua Lu

11 January 2023 in Annals of Medicine
Verified
Journal Article
Open access
XCXing-yu Cao
Xing-yu Cao
JCJia-Qi Chen
Jia-Qi Chen
HWHui Wang
Hui Wang
WMWei Ma
Wei Ma
WLWei-Wei Liu
Wei-Wei Liu
JWJian-Ling Wang
Jian-Ling Wang
Venetoclax monotherapy is an effective option for patients with acute myeloid leukemia (AML). Venetoclax has also been used in non-myeloablative conditioning allogeneic hematopoietic stem cell tran...

19 August 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
XCXing-yu Cao
Xing-yu Cao
HZHai-Fei Zhou
Hai-Fei Zhou
XLXiangjun Liu
Xiangjun Liu
XLXiao-Bo Li
Xiao-Bo Li
Introduction: The human leukocyte antigen (HLA) evolutionary divergence (HED) reflects immunopeptidome diversity and has been shown to predict the response of tumors to immunotherapy. Its impact on allogeneic hematopoietic stem cell transplantation (HSCT) is controversial in different studies.Methods: In this study, we retrospectively analyzed the clinical impact of class I and II HED in 225 acute lymphoblastic leukemia patients undergoing HSCT from related haploidentical donors. The HED for recipient, donor, and donor-recipient pair was calculated based on Grantham distance, which accounts for variations in the composition, polarity, and volume of each amino acid within the peptide-binding groove of two HLA alleles. The median value of HED scores was used as a cut-off to stratify patients with high or low HED.Results: The class I HED for recipient (R_HEDclass I) showed the strongest association with cumulative incidence of relapse (12.2 vs. 25.0%, P = 0.00814) but not with acute graft-versus-host disease. The patients with high class II HED for donor-recipient (D/R_HEDclass II) showed a significantly higher cumulative incidence of severe aGVHD than those with low D/R_HEDclass II (24.0% vs. 6.1%, P = 0.0027). Multivariate analysis indicated that a high D/R_HEDclass II was an independent risk factor for the development of severe aGVHD (P = 0.007), and a high R_HEDclass I had a more than two-fold reduced risk of relapse (P = 0.028). However, there was no discernible difference in overall survival (OS) or disease-free survival (DFS) for patients with high or low HED, which was inconsistent with the previous investigation.Discussion: While the observation are limited by the presented single center retrospective cohort, the results show that HED has poor prognostic value in OS or DFS, as well as the associations with relapse and aGVHD. In haploidentical setting, class II HED for donor-recipient pair (D/R_HEDclass II) is an independent and novel risk factor for finding the best haploidentical donor, which could potentially influence clinical practice if verified in larger cohorts.

5 March 2024 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
SXSong Xue
Song Xue
HSHui-Peng Sun
Hui-Peng Sun
XHXiao-Bing Huang
Xiao-Bing Huang
XCXue Chen
Xue Chen
TWTong Wang
Tong Wang
XCXing-yu Cao
Xing-yu Cao

6 October 2026 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
YSYun-Chao Su
Yun-Chao Su
JLJing Long
Jing Long
HWHui Wang
Hui Wang
MCMan Chen
Man Chen
QWQi-Sheng Wu
Qi-Sheng Wu
XCXing-yu Cao
Xing-yu Cao